{"nctId":"NCT00355615","briefTitle":"PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin","startDateStruct":{"date":"2006-07"},"conditions":["Familial Hypercholesterolemia"],"count":173,"armGroups":[{"label":"rosuva 5","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rosuvastatin"]},{"label":"rosuva 10","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rosuvastatin"]},{"label":"rosuva 20","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rosuvastatin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"rosuva ol","type":"OTHER","interventionNames":["Drug: Rosuvastatin"]}],"interventions":[{"name":"Rosuvastatin","otherNames":["Nexium"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female (at least 1 year post-menarche) children and adolescents (aged 10 -17 years) with heterozygous familial hypercholesterolemia (HeFH)\n\nExclusion Criteria:\n\n* Certain medical conditions and lab test results\n* History of a reaction to rosuvastatin or other statin drugs\n* Use of specified disallowed medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase","description":"Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value \\* 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.5","spread":"11.38"},{"groupId":"OG001","value":"-44.4","spread":"12.15"},{"groupId":"OG002","value":"-50.2","spread":"13.3"},{"groupId":"OG003","value":"-0.5","spread":"13.18"}]}]}]},{"type":"SECONDARY","title":"Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)","description":"Percent change from baseline in LDL-C after six week of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.3","spread":"12.22"},{"groupId":"OG001","value":"-45.2","spread":"11.15"},{"groupId":"OG002","value":"-50.0","spread":"11.42"},{"groupId":"OG003","value":"-0.6","spread":"13.63"}]}]}]},{"type":"SECONDARY","title":"Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment","description":"Percent of patients achieving LDL-C \\< 110 mg/dL out of the total patients in each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"40.9","spread":null},{"groupId":"OG002","value":"40.9","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in HDL-C","description":"Percent change in high-density lipoprotein cholesterol (HDL-C) after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"15.53"},{"groupId":"OG001","value":"10.1","spread":"14.19"},{"groupId":"OG002","value":"8.9","spread":"14.11"},{"groupId":"OG003","value":"7.6","spread":"17.89"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-HDL-C at 12 Weeks","description":"Percent change in non-HDL-C at 12 weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.3","spread":"9.98"},{"groupId":"OG001","value":"-42.8","spread":"11.50"},{"groupId":"OG002","value":"-47.7","spread":"13.50"},{"groupId":"OG003","value":"-0.8","spread":"11.89"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides (TG)","description":"Percent change in tryglycerides (TG) after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"49.07"},{"groupId":"OG001","value":"-14.2","spread":"29.66"},{"groupId":"OG002","value":"-7.9","spread":"55.88"},{"groupId":"OG003","value":"3.4","spread":"48.27"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol (TC)","description":"Percent change from baseline in total cholesteral after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.0","spread":"9.63"},{"groupId":"OG001","value":"-34.1","spread":"9.5"},{"groupId":"OG002","value":"-38.9","spread":"12.08"},{"groupId":"OG003","value":"0.2","spread":"10.53"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Apolipoprotein A-1 (ApoA-1)","description":"Percent change in ApoA-1 after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"9.69"},{"groupId":"OG001","value":"4.3","spread":"9.85"},{"groupId":"OG002","value":"3.9","spread":"10.68"},{"groupId":"OG003","value":"3.6","spread":"15.59"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Apolipoprotein B (ApoB)","description":"Percent change in ApoB after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.1","spread":"9.13"},{"groupId":"OG001","value":"-37.8","spread":"11.75"},{"groupId":"OG002","value":"-40.7","spread":"13.91"},{"groupId":"OG003","value":"-1.5","spread":"14.67"}]}]}]},{"type":"SECONDARY","title":"Percent Change in ApoB/ApoA-1","description":"Percent change in the ratio of ApoB/ApoA-1 after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.1","spread":"9.99"},{"groupId":"OG001","value":"-40.0","spread":"12.06"},{"groupId":"OG002","value":"-42.8","spread":"12.23"},{"groupId":"OG003","value":"-3.4","spread":"16.70"}]}]}]},{"type":"SECONDARY","title":"Percent Change in LDL-C/HDL-C","description":"Percent change in the ratio of LDL-C/HDL-C after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.4","spread":"11.36"},{"groupId":"OG001","value":"-48.6","spread":"13.26"},{"groupId":"OG002","value":"-53.6","spread":"12.85"},{"groupId":"OG003","value":"-5.5","spread":"17.98"}]}]}]},{"type":"SECONDARY","title":"Percent Change in TC/HDL-C","description":"Percent change in the ratio of TC/HDL-C after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.1","spread":"10.72"},{"groupId":"OG001","value":"-39.3","spread":"11.55"},{"groupId":"OG002","value":"-43.2","spread":"11.76"},{"groupId":"OG003","value":"-5.2","spread":"15.03"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Non-HDL-C/HDL-C","description":"Percent change in the ratio of non-HDL-C/HDL-C after 12 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.9","spread":"12.12"},{"groupId":"OG001","value":"-47.1","spread":"13.12"},{"groupId":"OG002","value":"-51.2","spread":"13.18"},{"groupId":"OG003","value":"-5.8","spread":"17.63"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0},"commonTop":["Headache","Nasopharyngitis","Influenza","Nausea","Fatigue"]}}}